EA024654B1 - Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии - Google Patents

Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии Download PDF

Info

Publication number
EA024654B1
EA024654B1 EA201001496A EA201001496A EA024654B1 EA 024654 B1 EA024654 B1 EA 024654B1 EA 201001496 A EA201001496 A EA 201001496A EA 201001496 A EA201001496 A EA 201001496A EA 024654 B1 EA024654 B1 EA 024654B1
Authority
EA
Eurasian Patent Office
Prior art keywords
zeg
amino acid
acid sequence
variable region
antibody
Prior art date
Application number
EA201001496A
Other languages
English (en)
Russian (ru)
Other versions
EA201001496A1 (ru
Inventor
Кристин Платер-Зиберк
Original Assignee
Эмджен Рисерч (Мьюник) Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Рисерч (Мьюник) Гмбх filed Critical Эмджен Рисерч (Мьюник) Гмбх
Publication of EA201001496A1 publication Critical patent/EA201001496A1/ru
Publication of EA024654B1 publication Critical patent/EA024654B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
EA201001496A 2008-04-29 2009-04-28 Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии EA024654B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12588008P 2008-04-29 2008-04-29
PCT/EP2009/055129 WO2009133103A1 (en) 2008-04-29 2009-04-28 Inhibitors of gm-csf and il-17 for therapy

Publications (2)

Publication Number Publication Date
EA201001496A1 EA201001496A1 (ru) 2011-06-30
EA024654B1 true EA024654B1 (ru) 2016-10-31

Family

ID=40810025

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001496A EA024654B1 (ru) 2008-04-29 2009-04-28 Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии

Country Status (16)

Country Link
US (1) US9353180B2 (enExample)
EP (1) EP2279001B1 (enExample)
JP (1) JP5771140B2 (enExample)
KR (2) KR20160117643A (enExample)
CN (2) CN102014958A (enExample)
AU (1) AU2009242088B2 (enExample)
BR (1) BRPI0911469A8 (enExample)
CA (1) CA2717987C (enExample)
EA (1) EA024654B1 (enExample)
ES (1) ES2557494T3 (enExample)
IL (1) IL209028A (enExample)
MX (1) MX2010011309A (enExample)
NZ (1) NZ587865A (enExample)
UA (1) UA102097C2 (enExample)
WO (1) WO2009133103A1 (enExample)
ZA (1) ZA201006353B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164101A1 (en) * 2009-04-30 2012-06-28 Jacques Galipeau Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
US20140044731A1 (en) * 2011-01-04 2014-02-13 Robert Nussenblatt Methods of treating age-related macular degeneration
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
NZ539271A (en) * 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
KR101395515B1 (ko) * 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLATER-ZYBERK CHRISTINE ET AL: "Highly efficient suppression of destructive arthritis by combined blockade of GM-CSF and IL-17 pathways in a TNF alpha-independent mouse model", ARTHRITIS & RHEUMATISM, WILEY INTERSCIENCE, US, vol. 58, no. 9, SUPPL. S, 269, 1 September 2008 (2008-09-01), US, XP002536615, ISSN: 0004-3591 *

Also Published As

Publication number Publication date
ZA201006353B (en) 2015-04-29
UA102097C2 (ru) 2013-06-10
AU2009242088A1 (en) 2009-11-05
US20110104172A1 (en) 2011-05-05
EA201001496A1 (ru) 2011-06-30
KR101681331B1 (ko) 2016-12-01
CA2717987A1 (en) 2009-11-05
ES2557494T3 (es) 2016-01-26
BRPI0911469A8 (pt) 2017-12-05
NZ587865A (en) 2012-06-29
JP2011518857A (ja) 2011-06-30
BRPI0911469A2 (pt) 2016-04-26
IL209028A (en) 2015-08-31
IL209028A0 (en) 2011-01-31
KR20100135937A (ko) 2010-12-27
CN102014958A (zh) 2011-04-13
WO2009133103A1 (en) 2009-11-05
JP5771140B2 (ja) 2015-08-26
CN104338136A (zh) 2015-02-11
CA2717987C (en) 2018-11-13
EP2279001B1 (en) 2015-09-30
EP2279001A1 (en) 2011-02-02
MX2010011309A (es) 2010-12-14
KR20160117643A (ko) 2016-10-10
US9353180B2 (en) 2016-05-31
AU2009242088B2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
Isho et al. Fantastic IgA plasma cells and where to find them
KR101320198B1 (ko) 신생물의 치료를 위한 조성물 및 방법
EA023148B1 (ru) Композиции на основе антагонистов pd-1 и их применение
EP3345620B1 (en) Methods and compositions for treating lupus
JP6245622B2 (ja) Ｉｌ−１８と分子標的抗体とを併用する癌治療薬
US12116391B2 (en) Dual cytokine fusion proteins comprising IL-10
JP5771140B2 (ja) 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤
JP2004527456A (ja) Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
EA013162B1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
IL282193B2 (en) Nk engager molecules and methods of use thereof
EP3007773B1 (en) Ige antibodies for the inhibition of tumor metastasis
EP3345618B1 (en) Agent for enhancing immunity to cancer by using allergin-1 antagonist
RU2770432C2 (ru) Комбинации для лечения рака, включающие abx196
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
EP2543388A1 (en) Drug for inflammatory bowel disease
EA006745B1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
US20220363776A1 (en) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CN112439060B (zh) Pd-l1免疫疗法的新用途
van Moorselaar Immunotherapy of renal cell carcinoma: clinical and experimental developments
HK1255653B (en) Methods and compositions for treating lupus
HK1131064B (en) Compositions and methods for treating a neoplasm
HK1255653A1 (en) Methods and compositions for treating lupus

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM